Table 1.
Clinical features of patients with either acute graft-versus-host disease of the skin or cutaneous involvement by lupus erythematosus.
| Parameter | Acute GVHD (n = 49) | LE (n = 14) | |
|---|---|---|---|
| Sex, M./F (%) | 28/11 (57/43) | 2/12 (14/86) | |
| Age at skin biopsy, years; mean (range) | 54.9 (20.9–74.4) | 60.6 (36.3–80.1) | |
| Hematopoietic cell transplantation graft type (GVHD; n = 48), n (%)* | |||
| Peripheral stem cells | 39 (81) | NA | |
| Bone marrow | 5 (10) | ||
| Unrelated cord blood | 4 (8) | ||
| Haematological diagnosis requiring HCT (GVHD), n (%) | |||
| AML | 17 (35) | NA | |
| MDS | 15 (31) | ||
| CML | 6 (12) | ||
| NHL | 2 (4) | ||
| ALL | 3 (6) | ||
| Multiple myeloma | 1 (2) | ||
| Other leukaemia | 1 (2) | ||
| Conditioning regimen (GVHD; n = 47*), n (%) | |||
| Fludarabine/TBI | 6 (13) | NA | |
| Fludarabine/TBI/cyclophosphamide | 6 (13) | ||
| Busulfan/cyclophosphamide | 6 (13) | ||
| Busulfan/fludarabine | 8 (17) | ||
| Melphalan/fludarabine | 12 (26) | ||
| Cyclophosphamide/TBI | 7 (15) | ||
| BEAM | 1 (2) | ||
| Cladribine/thiotepa/thymoglobulin | 1 (2) | ||
| Relationship of donor to recipient for HCT (GVHD; n = 47*), n (%) | |||
| Full sibling | 22 (47) | NA | |
| Haplotype-matched | 1 (2) | ||
| Other relative | 1 (2) | ||
| Unrelated | 23 (49) | ||
| Clinical subtype of LE skin lesions and SLE status, n (%) | |||
| Acute cutaneous LE, with SLE | NA | 6 (43) | |
| SCLE, without SLE | 4 (29) | ||
| SCLE, with SLE | 2 (14) | ||
| Cutaneous LE, NOS; without SLE | 2 (14) | ||
| Systemic immunosuppressive medications at time of skin biopsy, n† | |||
| Yes | 44/47** (94) | 3 (21) | |
| Tacrolimus | 19 | 0 | |
| Ciclosporin | 20 | 0 | |
| Mycophenolate mofetil | 8 | 0 | |
| Systemic corticosteroids | 11 | 2 | |
| Methotrexate | 0 | 2 | |
| Hydroxychloroquine | 0 | 2 | |
| Anatomical site of skin biopsy, n (%) | |||
| Head/neck | 3 (6.1) | 3 (21.4) | |
| Upper extremity (including shoulder) | 13 (26.5) | 6 (42.8) | |
| Lower extremity | 12 (24.5) | 0 | |
| Back | 7 (14.3) | 2 (14.3) | |
| Torso (abdomen/flank) | 11 (22.4) | 0 | |
| Chest | 3 (6.1) | 3 (21.4) | |
ALL, acute lymphocytic leukemia; AML, acute myeloid leukaemia; BEAM, BCNU (carmustine), etoposide, Ara-C (cytaribine) and melphalan; CML, chronic myeloid leukaemia; GVHD, graft-versus-host disease; HCT, haematopoietic cell transplantation; LE, systemic lupus erythematosus; MDS, myelodysplatic syndrome; NA, not applicable; NOS, not otherwise specified; SCLE, subacute cutaneous lupus erythematosus; TBI, total body irradiation.
Data not available for all patients
totals may exceed total number of patients on systemic immunosuppressant medications, as patients could be taking > 1 systemic immunosuppressive medication.